Novo Nordisk wins approval for diabetes drug
31 August 1998 00:00 [Source: ICB]
Novo Nordisk has received marketing approval in the European Union (EU) for its NovoNorm (repaglinide) diabetes treatment. The company said it expected to launch the product in a number of EU countries by the end of this year.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|
Subscribe Today Sample issue >> My Account/Renew >> Register for online access >> |
| ICIS Top 100 Chemical Companies |
|
|
Related Articles
- 10 May 13 12:00 Novo Nordisk 1Q 2013: Outlook for FY 2013
- 10 May 13 12:00 Novo Nordisk 1Q 2013: Sales of NovoNorm/Prandin/PrandiMet (oral antidiabetic products)
- 10 May 13 12:00 Novo Nordisk 1Q 2013: Sales of Victoza (GLP-1 therapy for type 2 diabetes)
- 18 Mar 13 12:00 New ultra-long effective insulin
- 11 Mar 13 12:00 In Nigeria, a new project prompts easier insulin access
- 07 Mar 13 12:00 Dainippon Sumitomo Pharma obtains approval for SUREPOST , a rapid-acting insulin secretagogue, for the additional indications of combination therapy with biguanides and with thiazolidinediones
- 18 Feb 13 12:00 Novo Nordisk A/S stung by FDA data request, stock down -27.85 (14.48%) at 3:02 PM ET
- 18 Feb 13 12:00 Tresiba now ready to be launched in Japan
- 13 Feb 13 12:00 Novo Nordisk 2012: Diabetes Care sales development
- 13 Feb 13 12:00 Novo Nordisk 2012: Outlook 2013
Latest News
- 22 May 13 15:18 Polish plastics consumption stalls in 2012 - trade group
- 22 May 13 14:30 China's Shandong Dongda set to restart PO, polyols units on 23 May
- 22 May 13 14:30 Austria's Borealis to begin Linz melamine turnaround next week
- 22 May 13 14:24 IFA'13: IFFCO signs MoU with Ameropa to export DAP from India
- 22 May 13 13:57 Germany potash workers get 3% wage hike in 21-month deal